Ranibizumab efficacy in central retinal vein occlusion: Beyond the 6th month of treatment

Poster Details

First Author: A.Liaska GREECE

Co Author(s):                                 

Abstract Details


To show the efficacy of ranibizumab in the treatment of macular edema due to central retinal vein occlusion beyond the 6th month of treatment.


Department of Ophthalmology, General Hospital of Lamia, Lamia, Greece


Case series, retrospective (chart review) study of the clinical course of 3 patients (men, age range 59, 66 and 78 years) with central retinal vein occlusion and recent (4 to 15 days) visual loss. Initial visual acuity (iVA), central foveal thickness (CCT), the number of ranibizumab injections, the follow up duration, last visual acuity tested, last CFT measurement performed were recorded.


Visual acuity increased from Counting Fingers to 7/10, 1/10 and 4/10 respectively (Wilcoxon signed rank test, p= 0.1088). The number of injections was 6, 8 and 8, follow up time was 7, 11 and 11 months, CFT from 630, 628 and 707 μm initially reached a minimum CFT of 240, 240 and 167 μm (Wilcoxon signed rank test, p= 0.1088). However, large CFT fluctuations were seen: 360, 460, 515 μm respectively. There was no eye with neovascular glaucoma. In one patient, after edema had decreased, vitreomacular traction was revealed and treated with ocriplasmine.


In central retinal vein occlusion monthly ranibizumab injections may improve visual acuity and lead to reduction of macular edema beyond the 6th month of treatment. However, repeated ranibizumab injections are necessary for result maintenance. Further studies with long follow up are needed.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy